Cadence

1.1 Identity and operating model

Cadence Solutions, Inc. was founded in 2020 and is headquartered in New York. Its service combines connected monitoring devices, an EMR-integrated workflow, supervised AI agents, and a dedicated clinical team to manage hypertension, heart failure, and type 2 diabetes between office visits. Chris Altchek is the founder and chief executive, while Kareem Zaki is identified as a cofounder. This is more operationally intensive than a software-only monitoring dashboard: Cadence participates in care delivery and insurer reimbursement while embedding into health-system workflows. That integration may strengthen retention, but it also makes clinical labor, reimbursement rules, and partner execution central dependencies rather than peripheral implementation details.[CO001, CO002, CO003]

1.2 Financing and stakeholders

Cadence announced a $100 million Series C on June 23, 2026, led by Spark Capital. STAT reported a $1.23 billion post-money valuation, while a separate company profile rounds the figure to $1.2 billion; the difference is treated as rounding rather than a conflicting financing event. Disclosed equity funding totals $241 million across the 2021 launch financing, the 2021 Series B, and the 2026 Series C. The round also brought health-system investors into the syndicate and added Spark partner Will Reed to the board. Those affiliations may aid distribution, but public evidence does not establish voting control, founder ownership, liquidation preferences, secondary activity, debt, or cash available after the financing.[CO004, CO005, CO006, CO013, CO014, CO016]

1.3 Scale and disclosure

By June 2026, Cadence said it served more than 100,000 active patients and worked with over 20 health systems. Its financing announcement also said annual recurring revenue tripled during 2025, but neither that announcement nor the reviewed company profile supplies a dollar ARR, revenue, profit, gross-margin, burn, or runway figure. A third-party company profile lists 516 employees, which is useful directional evidence but not a company-confirmed current headcount. The resulting scale picture is therefore strongest on patient and partner counts, weaker on workforce verification, and insufficient for deriving revenue per patient, capital efficiency, or cash runway. Funding raised must not be read as cash currently available.[CO007, CO008, CO009, CO015]

1.4 Milestones and diligence implications

Cadence progressed from a 2020 founding and 2021 venture rounds to product extensions in preventive, post-acute, and regulated hypertension care before its 2026 financing. The company profile reports launches of the Proactive Care Engine and AHA Connected Care in 2025 and selection of HypertensionOS for the FDA TEMPO pilot in August 2026. The principal adverse signal is business-model exposure rather than a documented company-specific enforcement action: STAT reported scrutiny of remote-monitoring reimbursement by the federal health department's watchdog and UnitedHealthcare, including concerns that the framework may enable low-quality care. Investors should verify billing quality, clinical oversight, and payer durability alongside the undisclosed governance and financial data.[CO001, CO004, CO006, CO010, CO011, CO012, CO014]

1.5 Exhibits

2.1 Market boundary and substitutes

The relevant market is the delivery of longitudinal, clinically managed care between visits for older adults with hypertension, heart failure, type 2 diabetes, and COPD. Cadence combines connected devices, an EMR-integrated workflow, supervised automation, and a physician-led clinical team; that makes it narrower than generic digital health and more service-intensive than device-only remote patient monitoring. The status quo is episodic in-person management, manual inbox follow-up, or a monitoring dashboard that leaves triage and intervention with the health system. Evidence from the allocated search pool was also screened for the Cadence Design Systems namesake, whose semiconductor market results are not evidence for Cadence Solutions.[CM001, CM002, CM003, CM015]

2.2 Evidence-constrained sizing

Available sources support three different, non-interchangeable sizing lenses. A broad need estimate says 56 million U.S. older adults live with chronic disease; Cadence reports a current deployment base above 100,000 active patients across more than 20 health systems; and the company states an ambition to treat one million people by the end of the decade. These are respectively a population denominator, observed company reach, and a corporate goal, not TAM, SAM, and SOM. No retained source supplies a defensible market revenue value, CAGR, condition-level overlap adjustment, reimbursement-weighted addressable population, or payer mix. A valuation model should therefore avoid converting these figures into a revenue opportunity without claims, reimbursement, retention, and capacity data.[CM004, CM005, CM006, CM014, CM015]

2.3 Buyer, user, payer, and adoption path

Health systems and their medical groups are the demonstrated institutional buyers, while patients and health-system clinicians are the day-to-day users. Cadence says reimbursement runs through billing infrastructure and at-risk contracts, but public material does not disclose payer mix, contract allocation, pricing, or the executive budget owner. Adoption therefore appears to depend on an integrated clinical-service sale rather than a stand-alone software purchase: connected devices collect readings, Cadence's team handles routine monitoring and escalation, and the workflow connects back to the health system. Reported capacity benefits and expansion into additional systems are useful demand signals, but procurement duration and implementation cost remain unquantified.[CM002, CM007, CM008, CM010, CM011, CM016]

2.4 Drivers, constraints, and valuation relevance

Demand is supported by clinician shortages, a large chronic-disease burden, and health systems' need to manage patients between visits without adding equivalent physician headcount. Cadence also cites a 27% reduction in hospital admissions, while third-party coverage describes expansion toward more health systems and value-based care. The main adoption constraints are trust, clinical accountability, reimbursement durability, and patient acceptance of AI-enabled medical devices; TechTarget reports that one-third of respondents in a 2025 survey were concerned about their safety. For valuation, deployment growth is evidence of product-market pull, but it is not a substitute for market revenue, unit economics, payer concentration, implementation cost, or independently verified ROI.[CM009, CM011, CM012, CM013, CM014]

2.5 Exhibits

3.1 Landscape and buyer alternatives

The relevant competitive set is broader than pure remote-patient-monitoring software. The retained registry identifies scaled managed-care peers including HealthSnap, Health Recovery Solutions, TimeDoc Health, and CoachCare, while the buyer can also assemble devices, monitoring software, internal clinical operations, and existing episodic care. Cadence reported more than 100,000 active patients across more than 20 health systems in June 2026 and raised a $100 million Series C, giving it meaningful scale and capital for expansion. Peer scale is not trivial: the retained registry attributes about 80,000 patient programs across about 200 systems and groups to HealthSnap, more than 400 provider organizations to Health Recovery Solutions, and more than 150,000 patients to CoachCare. Those figures come from one low-reputation registry and are directional rather than independently verified benchmarks. Internal build and the status quo remain material substitutes because health systems retain clinical protocols, existing patient relationships, and workflow control even when they outsource monitoring and care-team capacity.[CP003, CP004, CP005, CP011, CP012, CP013, CP014, CP015]

3.2 Service model, capabilities, and trust posture

Cadence's clearest supported distinction is operating-model depth. Independent coverage describes the company as a clinical service rather than only a monitoring platform, supported by a medical group with more than 300 staff. Customer and partner materials describe supervised agents reviewing daily data while clinicians complete medication recommendations inside the health system's existing care relationship. Cadence and secondary coverage also describe direct electronic-medical-record and workflow integration. The company reports a 3.5-minute median response time for incoming vitals alerts and says 55% are resolved without human adjustment, but these operating metrics are company-originated and are not a neutral comparison with peers. The capability matrix therefore records only features stated in retained sources and marks unsupported competitor cells as unknown. Cadence appears more vertically integrated than a device-dashboard vendor, yet that conclusion does not establish superior safety, outcomes, regulatory posture, or total cost against named alternatives.[CP001, CP002, CP006, CP007, CP008, CP009, CP011, CP012, CP013, CP014]

3.3 Commercial model, distribution power, and switching

Public commercial evidence is thin. One industry-operator commentary says Cadence charges insurers a monthly remote-care fee rather than a per-alert or per-device fee; no retained source provides the fee, realized contract price, discounting, minimum commitment, reimbursement split, or contract duration. Distribution is supported more clearly: Cadence embeds into health-system medical groups, clinical protocols, electronic records, and branded care relationships. That integration likely creates implementation and process-switching friction, because replacement would require reworking workflows and clinical accountability rather than swapping a standalone dashboard. It does not prove contractual lock-in, exclusivity, low churn, or an inability to multi-home. Health-system venture participation and customer references may strengthen channel access, but they should not be treated as independent product validation. The central diligence need is contract-level evidence comparing Cadence's net economics and implementation burden with managed RPM peers and an internal-build case.[CP006, CP007, CP010, CP015]

3.4 Moat durability and displacement risk

The defensible thesis is not that Cadence alone can monitor chronic-care patients. Retained descriptions show competitors offering devices, RPM, chronic-care management, Advanced Primary Care Management, staffed monitoring, and national clinical teams. Cadence's stronger case is the combination of workflow integration, clinical-service ownership, health-system distribution, reported operating responsiveness, and evidence claims. Even that combination may be replicated or unbundled: managed-care peers can deepen clinical services, health systems can internalize higher-value workflows, and incumbent workflow vendors could extend from the electronic record into supervised automation. The positioning map is therefore an evidence-constrained taxonomy, not a performance ranking; its ordinal coordinates encode only the service ownership and integration described in the retained sources. No independent head-to-head benchmark, competitor pricing set, win-loss data, churn evidence, or adverse competitor study was available. Durability depends on proving outcome and economic superiority after implementation, not merely on attaching AI to a familiar RPM model.[CP001, CP002, CP006, CP007, CP011, CP012, CP013, CP014, CP015, CP016]

3.5 Exhibits

4.1 Revenue engine and pricing

Cadence describes a hybrid revenue engine rather than a simple software subscription: care is reimbursed through billing infrastructure and at-risk contracts, while its preventive-primary-care offer is marketed as Medicare covered. An industry operator separately describes a monthly insurer fee rather than per-alert or per-device pricing, but that account is not a contract and does not establish realized price. The clearest public rate is for the ACCESS model, where STAT reported $180 to $420 per patient in the first year depending on condition, with full payment contingent on outcomes. STAT also reported this is materially below roughly $100 per month under a common RPM model. The mix can therefore produce recurring revenue, but price, code mix, discounts, and outcome-risk allocation remain private.[CI001, CI002, CI003, CI005, CI006]

4.2 Traction and operating-leverage signals

Public traction is substantial but mostly non-financial. Cadence reported that annual recurring revenue tripled in 2025, more than 100,000 active patients, and relationships with over 20 health systems in June 2026. Its March ACCESS announcement used a different denominator, saying more than 130,000 patients had been served since 2021; that cumulative figure should not be compared directly with active patients. The company also advertises 85,000 clinician hours returned annually and 99% of alerts resolved without physician escalation. Those measures suggest automation may improve labor leverage, but they do not establish recognized revenue, gross margin, or contribution margin. Absolute ARR and profit remain undisclosed in the retained evidence.[CI007, CI009, CI010, CI011, CI012, CI013, CI016]

4.3 Capital adequacy and policy dependence

Cadence raised a $100 million Series C in June 2026 and said the capital would support health-system expansion, AI-agent development, and growth in value-based care. The round extends financing capacity, but funding raised is not cash available: without current cash, burn, debt, working-capital requirements, or committed expansion spend, runway and the next financing trigger cannot be calculated. Policy exposure compounds that uncertainty. Legis1 reported that a proposed 2027 CMS rule would restrict payment for outsourced third-party RPM vendors and require more physician involvement. Because that rule is proposed rather than final, it is a scenario risk, not a current revenue loss; nevertheless, it could raise delivery cost or pressure the billing-based stream.[CI008, CI014, CI015]

4.4 Financial verdict and diligence blockers

Revenue quality is directionally attractive but not yet underwritable from public evidence. Recurring reimbursement, health-system distribution, and outcome-linked contracts can support durable demand, while relative ARR growth and patient scale point to commercial momentum. The same model carries labor, clinical-service, and reimbursement exposure that cannot be quantified from the available disclosures. Company-reported clinician-capacity gains are useful operating proxies, not proof of gross-margin expansion. The investment case therefore depends on a private-data review of recognized revenue by stream and payer, realized price, gross-to-net deductions, clinical labor and device costs, cohort contribution margin, customer concentration, cash, burn, runway, debt obligations, and downside economics under lower RPM reimbursement.[CI001, CI004, CI007, CI012, CI013, CI015, CI016]

4.5 Exhibits

5.1 Product portfolio and customer workflow

Cadence is delivered as a clinical service rather than a standalone monitoring dashboard. Its public portfolio spans 24/7 Preventive Primary Care, Remote Patient Care, Post-Acute Care, and the narrower HypertensionOS prescription-software program. Across these products, the workflow begins with home measurements and engagement signals, moves through risk identification and protocol-driven action, and escalates decisions that require clinical judgment. The model therefore bundles software, connected devices, clinical operations, and workflow integration. This breadth is strategically useful because it addresses the health system's labor constraint, but it also means product quality depends on coordinated service delivery rather than software performance alone.[CE001, CE002, CE003, CE005, CE006]

5.2 Architecture and operating model

The observable architecture has five layers: patient devices and interactions, longitudinal signal ingestion, Clinical Intelligence, a multidisciplinary care team, and the partner health system's EMR and clinical workflow. Cadence says its agents monitor vitals daily, surface risk, support medication changes, and provide lifestyle coaching under clinical protocols and human supervision. Public third-party material also identifies AWS, Kubernetes, Terraform, and GitHub Actions in the hiring surface, but that signal is insufficient to verify production topology or resilience. The integration claim is consequently credible at the workflow level while the implementation details remain a diligence item.[CE003, CE004, CE005, CE006, CE010, CE011]

5.3 Maturity, automation, and differentiation

Cadence's strongest disclosed differentiation is the combination of an EMR-native product, its own clinical operating layer, and data generated through continuous care delivery. Company materials report 85,000 clinician hours returned annually, 99% of alerts resolved without physician escalation, and a 3.5-minute median response time for incoming vital alerts; the funding announcement separately says 55% are resolved without human adjustment. These measures are directionally consistent with workflow automation, but their denominators and definitions differ and should not be treated as one conversion funnel. The scale signal is meaningful, while independent validation of the automation metrics remains limited in this assigned evidence set.[CE007, CE008, CE009, CE016]

5.4 Controls, roadmap, and technical risk

The public control model is clinician-supervised: Cadence describes safety guardrails, health-system protocols, and physician control over consequential decisions. HypertensionOS's reported selection for the FDA TEMPO pilot is evidence of regulatory engagement, not evidence of approval or clearance. Cadence says new capital will support additional health-system expansion, AI-agent development, and value-based-care models, which increases the importance of change control, monitoring, and auditable protocol governance. The retained evidence does not establish security certifications, privacy architecture, uptime history, disaster recovery objectives, model-validation methods, or incident-response performance; those remain material underwriting gaps rather than proof that the controls are absent.[CE003, CE012, CE013, CE014, CE015]

5.5 Exhibits

6.1 Customer model and segments

Cadence operates a multi-stakeholder model in which health systems are the principal institutional buyers and workflow owners, clinicians use an EMR-integrated care service, and older adults with hypertension, heart failure, or type 2 diabetes are the end users. The company says its model is reimbursed through billing infrastructure and at-risk contracts, making payer economics and health-system implementation part of the buying decision rather than an afterthought. Public evidence also distinguishes several care surfaces: remote patient care, preventive primary care, and post-acute support. This breadth can expand account value, but it also creates multiple approval, integration, enrollment, and reimbursement steps before a named affiliation becomes durable utilization.[CU001, CU005, CU011, CU012]

6.2 Adoption trajectory and reference quality

The strongest adoption signal is the June 2026 scale claim of more than 100,000 active patients and more than 20 health systems, reported by Cadence and repeated by an independent trade publication. A customer-issued April 2026 announcement described a base of more than 90,000 patients, while an independent company profile lists a longer trajectory from more than 18,000 patients in March 2024 to more than 100,000 in June 2026. Named evidence includes Duke Health, Texas Health Resources, and Memorial Hermann, but the sources mostly establish affiliations or planned service introductions. They do not disclose deployment-level enrolled populations, contract value, or customer-specific clinical outcomes, so the named references should not be treated as equivalent to mature, fully quantified production accounts.[CU002, CU003, CU004, CU005, CU006]

6.3 Durability, expansion, and concentration

Cadence's disclosed operating model creates a plausible expansion path from initial health-system affiliation through EMR integration, patient enrollment, continuous monitoring, clinical response, and additional care programs. Company-reported operating metrics indicate substantial activity, including 24,000 medication titrations in 2025, 85,000 clinician hours returned annually, 99% of alerts resolved without physician escalation, and 4.9/5 patient satisfaction. These metrics do not substitute for retention evidence: the assigned public sources disclose no NRR, GRR, churn, renewal rate, contract length, or cohort retention. They also do not quantify revenue or patient concentration by health system, payer, or channel. Health-system investors and affiliations may support distribution, but they also make procurement, integration, and partner dependence central diligence questions.[CU007, CU008, CU009, CU010, CU013, CU014, CU015, CU016]

6.4 Exhibits

7.1 Regulatory and reimbursement path

HypertensionOS is operating inside a novel policy pathway rather than on the strength of a conventional clearance. Reporting on the TEMPO pilot says participation is neither FDA clearance nor an endorsement of effectiveness; it instead permits controlled deployment under enforcement discretion while evidence is generated. The bounded scope, licensed-user requirement, and excluded patient groups reduce immediate clinical exposure, but they also constrain addressable use and make evidence quality a commercialization dependency. Payment risk is similarly material. STAT reports first-year ACCESS payments of $180-$420 per patient, with full payment contingent on outcomes, versus roughly $100 per month under a common RPM model. The investment case therefore depends on automation lowering clinical labor enough to offset lower, outcome-contingent reimbursement without weakening escalation or prescribing controls.[CR004, CR005, CR006, CR009, CR014]

7.2 Clinical operations, quality, and security

Cadence presents a human-in-the-loop architecture: AI agents perform protocol-driven work, physicians retain control, and most alerts are resolved without physician escalation. Those controls are directionally appropriate, but the reported scale of automation creates a large monitoring surface. Cadence says it completed 24,000 medication titrations in 2025, while its evidence page reports that 75% of a hypertension cohort still measured vitals at six months. Device continuity, patient nonresponse, alert quality, medication-review latency, and escalation staffing are therefore operating controls rather than implementation details. The retained evidence describes what a buyer should verify for privacy and PHI handling, but it does not disclose Cadence's certifications, incident history, access-control testing, recovery objectives, or device-replacement service levels. Absence of those disclosures is a diligence gap, not evidence that incidents have or have not occurred.[CR001, CR002, CR010, CR011, CR012, CR013]

7.3 Partner, dependency, and financial exposure

Cadence reports more than 100,000 active patients across more than 20 health systems, which demonstrates scale but does not reveal revenue concentration, renewal rights, termination exposure, or payer mix. Delivery also depends on connected devices, EHR integration, a clinical workforce, and reimbursement programs; disruption in any layer can impair both outcomes and billability. Public financial visibility remains thin. An independent profile says Cadence has not published dollar revenue or profit while reporting that annual recurring revenue tripled in 2025. The June 2026 financing is evidence of capital raised, not current cash, burn, or runway. Until management provides partner-level economics, gross margin after clinical labor and devices, claims-denial experience, and liquidity, the residual exposure is execution risk rather than a quantifiable solvency conclusion.[CR003, CR008, CR011, CR014, CR015, CR016]

7.4 Monitoring framework and thesis-break triggers

The risk posture should be monitored through evidence that maps directly to the operating model. Regulatory progress means a defined path beyond pilot discretion and prospective safety evidence in the intended population. Reimbursement resilience means positive contribution margin under ACCESS payment bands after clinical labor, devices, support, and outcome adjustments. Clinical resilience means stable adverse-event rates, alert precision, medication-review latency, device uptime, and six-month engagement as patient volume grows. Commercial resilience means no single health system or payer can materially impair revenue through nonrenewal. A failure to produce auditable controls for medication changes and PHI, a material patient-safety event attributable to automation, loss of the regulatory pathway, or persistently negative cohort contribution margin should break the thesis rather than be treated as a temporary execution miss.[CR004, CR006, CR009, CR010, CR012, CR013, CR015, CR016]

7.5 Exhibits

8.1 Decision and valuation stance

The recommendation is research-more, with medium confidence, high risk, and an unproven valuation stance. The June 2026 Series C supplies a transaction marker of approximately $1.2 billion to $1.23 billion post-money, not proof that the price offers an attractive risk-adjusted return. Cadence reports meaningful operating scale, and third-party commentary points to substantial 2026 revenue, but no public source in the assigned evidence set provides current audited revenue, gross margin, cash burn, retention, or cash available after the round. Those omissions make a target return, hold period, and exit value non-quantifiable without private diligence. Entry should therefore be conditioned on financial verification and security terms rather than company quality alone.[CV002, CV004, CV012, CV015, CV016]

8.2 Financing context and entry discipline

Cadence announced a $100 million Series C led by Spark Capital, with the company and multiple independent summaries identifying a broad investor syndicate. Third-party sources place the post-money value between $1.2 billion and $1.23 billion. Dividing that mark by SiliconSnark's Forbes-attributed forecast of $140 million in annualized revenue at year-end 2026 produces an illustrative 8.6x to 8.8x multiple, but this is a forward-looking annualized-revenue comparison rather than a current ARR or audited-revenue multiple. The same transaction figures imply roughly 8.1% to 8.3% primary dilution before option-pool changes, liquidation preferences, participation rights, debt, and other securities. Because those terms are not public, headline post-money value is an incomplete measure of common-equity entry economics.[CV001, CV002, CV004, CV005, CV006, CV012, CV013]

8.3 Thesis, anti-thesis, and comparable context

The thesis rests on scale, workflow integration, and evidence that supervised automation can extend scarce clinical capacity. Cadence says it treats more than 100,000 active patients across more than 20 health systems and reports lower admissions in its cited research. It also publishes two operational automation measures with different denominators: alerts resolved without human adjustment and alerts resolved without physician escalation. These should not be merged into one autonomy metric. The anti-thesis is that reimbursement scrutiny, clinician oversight, health-system procurement, and regulatory execution may keep the business services-heavy while the current valuation anticipates software-like leverage. Selected digital-health IPO revenue multiples provide directional context, but their dates, business mixes, liquidity, and accounting bases differ too much to validate Cadence's private round price directly.[CV007, CV008, CV009, CV010, CV011, CV014]

8.4 Scenarios, exit readiness, and diligence asks

The scenario framework is deliberately signal-based rather than a false-precision valuation model. A bull case requires verified revenue scale, improving gross margin as supervised AI expands, durable reimbursement, and evidence that new health-system deployments do not add proportionate clinical labor. A base case assumes continued adoption but treats the June 2026 financing as the only public price marker until financial and preference data are supplied. A bear case is triggered by reimbursement compression, delayed regulated-AI deployment, weak retention, or labor intensity that does not decline. Exit readiness remains uncertain because the evidence set does not establish profitability, audited controls, or a clean preference stack. The final diligence request is a cohort-level revenue, margin, retention, labor, cash, and capitalization package reconciled to the financing documents.[CV003, CV009, CV010, CV012, CV013, CV015, CV016]

8.5 Exhibits